Protara Therapeutics Inc. (TARA)
NASDAQ: TARAHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TARA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $153.06M
- EPS (TTM)
- -$1.38
- Dividend yield
- None
- 52-week range
- 2.51 – 7.82
- Day range
- 2.51 – 2.67
- Volume / Avg
- 731.35K / 801.43K
- Beta
- —
- Shares outstanding
- 59.10M
52-week range
TARA stock today
Shares of Protara Therapeutics (TARA) finished higher on Oct 7 at $2.59, a gain of 1.37% or $0.035 per share, versus the S&P 500's 0.22% decline. At this level, TARA sits near the bottom of its 52-week range of $2.51 to $7.82: 66.9% below the high, set on Nov 24, 2025 and 3.2% above the low. TARA is down 51.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 46.3%.
Protara Therapeutics has posted a net loss over the last twelve months (EPS of -$1.38), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Protara Therapeutics
Company profileProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jesse Shefferman
- Headquarters
- New York, NY
- Employees
- 46
- IPO year
- 2014
- Website
- protaratx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$25.71+892.66%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Protara Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | +3.45% | $151.87M | vs TARA |
| VYGRVoyager Therapeutics Inc. | 2.47 | +0.41% | $152.20M | vs TARA |
| CDXSCodexis Inc. | 1.41 | +3.68% | $154.40M | vs TARA |
| KRROKorro Bio Inc. | 10.49 | +7.48% | $154.47M | vs TARA |
| MOLNMolecular Partners AG ADR | 3.81 | +0.79% | $145.94M | vs TARA |
| CHRSCoherus Oncology Inc. | 1.01 | -1.94% | $156.05M | vs TARA |
| NERVMinerva Neurosciences Inc | 3.27 | -4.66% | $156.13M | vs TARA |
| ALXOALX Oncology Holdings Inc. | 1.13 | +1.80% | $156.25M | vs TARA |
Indexes, lists and sector
Appears in lists
Protara Therapeutics stock FAQ
What is Protara Therapeutics's stock price today?
TARA last traded at $2.59 as of Oct 7, 4:00 PM EDT, up 1.37% on the day. Prices are delayed at least 15 minutes.
Does Protara Therapeutics pay a dividend?
No. Protara Therapeutics does not currently pay a regular cash dividend.
Who is Protara Therapeutics's CEO?
Mr. Jesse Shefferman is the chief executive officer of Protara Therapeutics Inc., which has about 46 employees.
Has TARA ever split its stock?
Yes. The most recent TARA stock split was a 1-for-40 split on Jan 10, 2020.
What is the TARA 52-week high?
The 52-week high for TARA is $7.82 and the 52-week low is $2.51. The stock is currently 66.9% below its high.